Nektar Wins $90 Million Verdict Against Eli Lilly Over Rezpeg Partnership
California jury found Lilly breached good faith in the 2017 rezpeg deal and awarded Nektar $90 million plus interest. Lilly plans to appeal.
/ 111 items
#LLY↓
FDA Approves Lilly’s Once-Weekly Insulin Onswik, Challenging Novo’s Awiqli
FDA clears Lilly’s Onswik, a once-weekly basal insulin for adults with type 2 diabetes. It may cut 300+ shots a year and now competes with Novo’s Awiqli.
Nektar Shares Slide as Jury Weighs Lilly Lawsuit Over Rezpeg
Investors are watching liability and damages in Nektar’s breach case against Lilly, a key swing factor for the Rezpeg program. Analysts still see damages as the hard issue.
VKTX Jumps After Viking Shows Monthly and Every-Other-Week Shots Can Hold Most Weight Loss
Viking reported 16–19% weight loss at week 21 and strong maintenance on monthly dosing. GI side effects in the later phase looked like placebo.
Novo Shares Slide as Long-Term Goals Disappoint Market
Distant 2030 goals failed to ease concerns over patents and Lilly.
Twist and Ginkgo Join Lilly’s TuneLab to Speed Antibody Discovery With AI and Lab Data
Twist Bioscience and Ginkgo Datapoints join Eli Lilly’s TuneLab to pair lab testing with AI for faster antibody drug discovery.